Filing Details
- Accession Number:
- 0001610717-24-000490
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-19 16:35:50
- Reporting Period:
- 2024-09-17
- Accepted Time:
- 2024-09-19 16:35:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1885522 | Neumora Therapeutics Inc. | NMRA | Biological Products, (No Disgnostic Substances) (2836) | 844367680 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1992908 | A. Robert Lenz | C/O Neumora Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown MA 02472 | Head Of R&D | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-09-17 | 30,788 | $11.81 | 339,205 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-09-18 | 10,676 | $12.09 | 328,529 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024.
- This transaction was executed in multiple trades in prices ranging from $11.5985 to $12.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $12.00 to $12.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Billionaire Hedge Funds
